Results from the FUTURE 2 study show that secukinumab improves signs and symptoms in patients with active psoriatic arthritis through 2 years of therapy.
All articles by Gary Rothbard, MD, MS
Lowering tumor necrosis factor inhibitor dosage by one-third yielded excellent results in terms of safety, clinical effectiveness, and tolerability in patients with rheumatoid arthritis.
Latest News Your top articles for ThursdayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses